

2/5

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
28 June 2001 (28.06.2001)

PCT


(10) International Publication Number
WO 01/45689 A2

- (51) International Patent Classification⁷: **A61K 31/00**
- (21) International Application Number: **PCT/US00/35009**
- (22) International Filing Date:
22 December 2000 (22.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/171,693 22 December 1999 (22.12.1999) US
- (71) Applicant (for all designated States except US): **SUGEN, INC.** [US/US]; 230 East Grand Avenue, South San Francisco, CA 94080-4811 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LIPSON, Ken** [US/US]; 733 Costa Rica Avenue, San Mateo, CA 64402 (US). **MCMAHON, Gerald** [US/US]; P.O. Box 807, Kenwood, CA 94542 (US).
- (74) Agent: **ISACSON, John, P.**; Foley and Lardner, 3000 K Street N.W., Suite 500, Washington, DC 20007-5109 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHODS OF MODULATING *c-KIT* TYROSINE PROTEIN KINASE FUNCTION WITH INDOLINONE COMPOUNDS**



CSF-1r/ *c-fms*
SCFr/ *c-kit*
flt-3/flk-2



(57) Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity *c-kit* kinase.

WO 01/45689 A2

**METHODS OF MODULATING *c-KIT* TYROSINE PROTEIN KINASE
FUNCTION WITH INDOLINONE COMPOUNDS**

5 This application claims priority to U.S. Serial No. 60/171,693, filed December 22, 1999, the entirety of which is hereby incorporated by reference.

FIELD OF THE INVENTION

10 The present invention relates to methods, compounds, and compositions for inhibiting cell proliferative disorders. The invention is particularly useful for inhibiting cell proliferative disorders characterized by overactivity and/or inappropriate activity of a *c-kit* kinase.

15 BACKGROUND OF THE INVENTION

 The following description of the background of the invention is provided to aid in understanding the invention, but is not admitted to describe or constitute prior art to the invention.

20 Kit signaling is critical for fetal gonadal development, and continues to play a role in adult fertility (Mauduit et al. (1999) Human Reproduction Update 5:535-545). Spermatogenesis is inhibited in the absence of SCF (Ohta et al. (2000) Development 127:2125-2131) or the ability of Kit to signal through the PI3 kinase pathway (Blume-Jensen et al. (2000) Nature Genetics 24:157-162; Kissel et al. (2000) EMBO Journal
25 19:1312-1326). Kit expression has also been observed to be lower in sub-fertile testes than in normal testicular tissue (Feng et al. (1999) Fertility & Sterility 71:85-89). Kit signaling is also important for oogenesis and folliculogenesis (Parrott & Skinner (1999) Endocrinology 140:4262-4271; Driancourt et al. (2000) Reviews of Reproduction 5:143-152). These observations suggest that Kit kinase inhibitors would reduce both
30 male and female fertility.

 As a key mediator of mast cell function, Kit may play a role in pathologies associated with mast cells. For example, mast cells have been associated with interstitial fibrosis in chronic rejection of human renal allografts (Pardo et al. (2000) Virchows Archiv 437:167-172). Mast cells have also been implicated in liver allograft

rejection (Yamaguchi et al. (1999) *Hepatology* 29:133-139) and in liver fibrosis, where hepatic stellate cells produce the SCF that recruits the mast cells (Gaca et al. (1999) *J. Hepatology* 30:850-858). These observations suggest the Kit kinase inhibitors may help prevent organ rejection and fibrosis.

5 Mast cells have also been implicated in the pathology of multiple sclerosis (Secor et al. (2000) *J. Experimental Medicine* 191:813-822) and ischemia-reperfusion injury (Andoh et al. (1999) *Clinical & Experimental Immunology* 116:90-93) in experimental models using mice with mutant Kit receptors that are deficient in mast cells. In both cases, the pathology of the disease was significantly attenuated relative to
10 mice with normal Kit and mast cells populations. Thus, the role of mast cells in these diseases suggests that Kit kinase inhibitors might be useful therapeutics.

Cellular signal transduction is a fundamental mechanism whereby extracellular stimuli are relayed to the interior of cells and subsequently regulate diverse cellular processes. One of the key biochemical mechanisms of signal transduction involves the
15 reversible phosphorylation of proteins. Phosphorylation of polypeptides regulates the activity of mature proteins by altering their structure and function. Phosphate most often resides on the hydroxyl moiety (-OH) of serine, threonine, or tyrosine amino acids in proteins.

Enzymes that mediate phosphorylation of cellular effectors generally fall into
20 two classes. The first class consists of protein kinases which transfer a phosphate moiety from adenosine triphosphate to protein substrates. The second class consists of protein phosphatases which hydrolyze phosphate moieties from phosphoryl protein substrates. The converse functions of protein kinases and protein phosphatases balance and regulate the flow of signals in signal transduction processes.

25 Protein kinases and protein phosphatases are generally divided into two groups: receptor and non-receptor type proteins. Most receptor-type protein tyrosine phosphatases contain two conserved catalytic domains, each of which encompasses a segment of 240 amino acid residues. Saito, *et al.*, 1991, *Cell Growth and Diff.* 2:59-65. Receptor protein tyrosine phosphatases can be subclassified further based upon the
30 amino acid sequence diversity of their extracellular domains. Saito, *et al.*, *supra*; Krueger, *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89:7417-7421.

Protein kinases and protein phosphatases are also typically divided into three classes based upon the amino acids they act upon. Some catalyze the addition or hydrolysis of phosphate on serine or threonine only, some catalyze the addition or hydrolysis of phosphate on tyrosine only, and some catalyze the addition or hydrolysis of phosphate on serine, threonine, and tyrosine.

Tyrosine kinases can regulate the catalytic activity of other protein kinases involved in cell proliferation. Protein kinases with inappropriate activity are also involved in some types of cancer. Abnormally elevated levels of cell proliferation are associated with receptor and non-receptor protein kinases with unregulated activity.

In addition to their role in cellular proliferation, protein kinases are thought to be involved in cellular differentiation processes. Cell differentiation occurs in some cells upon nerve growth factor (NGF) or epidermal growth factor (EGF) stimulation. Cellular differentiation is characterized by rapid membrane ruffling, cell flattening, and increases in cell adhesion. (Chao, 1992, *Cell* 68:995-997).

In an effort to discover novel treatments for cancer and other diseases, biomedical researchers and chemists have designed, synthesized, and tested molecules that inhibit the function of protein kinases. Some small organic molecules form a class of compounds that modulate the function of protein kinases. Examples of molecules that have been reported to inhibit the function of protein kinases are bis-monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642), vinylene-azaindole derivatives (PCT WO 94/14808), 1-cyclopropyl-4-pyridyl-quinolones (U.S. Patent No. 5,330,992), styryl compounds (by Levitzki, *et al.*, U.S. Patent No. 5,217,999, and entitled "Styryl Compounds which Inhibit EGF Receptor Protein Tyrosine Kinase, Lyon & Lyon Docket No. 208/050), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1), seleoindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic compounds (PCT WO 92/21660), and benzylphosphonic acid compounds (PCT WO 91/15495).

The compounds that can traverse cell membranes and are resistant to acid hydrolysis are potentially advantageous therapeutics as they can become highly bioavailable after being administered orally to patients. However, many of these protein kinase inhibitors only weakly inhibit the function of protein kinases. In

addition, many inhibit a variety of protein kinases and will therefore cause multiple side-effects as therapeutics for diseases.

Despite the significant progress that has been made in developing compounds for the treatment of cancer, there remains a need in the art to identify the particular
5 structures and substitution patterns that form the compounds capable of modulating the function of particular protein kinases.

SUMMARY OF THE INVENTION

10 The present invention is directed in part towards indolinone compounds and methods of modulating the function of protein kinases with these compounds. In addition, the invention describes methods of treating and preventing protein kinase-related abnormal conditions in organisms with a compound identified by the methods described herein. Furthermore, the invention pertains to pharmaceutical compositions
15 containing compounds identified by methods of the invention.

The present invention features indolinone compounds that potently inhibit receptor protein kinases of the *c-kit* family and related products and methods. Other inhibitors and/or activators of *c-kit* protein kinases can be obtained by adding chemical substituents to an unsubstituted indolinone compound (See Formulas I and II, below).
20 The compounds of the invention provide therapeutics and/or prophylactics for diseases associated with one or more functional *c-kit* protein kinases. Certain types of cancer fall into this class of diseases, along with certain immune disorders associated with the over-production or over-stimulation of mast cells. The compounds can be modified such that they are specific to their target or targets and will subsequently cause few side
25 effects. These properties are significant improvements over the currently utilized cancer therapeutics that cause multiple side effects and deleteriously weaken patients.

The compounds, compositions, and methods of the invention will minimize or obliterate certain types of solid tumors and leukemias by inhibiting the activity of the *c-kit* receptor protein kinases, or will at least modulate or inhibit tumor growth and/or
30 metastases. Certain types of cancer, such as Small Cell Lung Cancer (SCLC), express both the *c-kit* receptor protein kinase and Stem Cell Factor (SCF), a *c-kit* ligand.

While a precise understanding of the mechanism by which compounds inhibit phosphotyrosine kinases (PTKs) (*e.g.*, the *c-kit* receptor kinase, a transmembrane tyrosine kinase growth factor receptor) is not required in order to practice the present invention, the compounds are believed to interact with the amino acids of the PTKs' catalytic region. PTKs typically possess a bi-lobate structure, and ATP appears to bind in the cleft between the two lobes in a region where the amino acids are conserved among PTKs; inhibitors of PTKs are believed to bind to the PTKs through non-covalent interactions such as hydrogen bonding, Van der Waals interactions, hydrophobic interactions, and ionic bonding, in the same general region that ATP binds to the PTKs.

More specifically, it is thought that the oxindole component (See Formula III, below) of the compounds of the present invention binds in the same general space occupied by the adenine ring of ATP. Specificity of a PTK inhibitor for a particular PTK may be conferred by interactions between the constituents around the oxindole core with amino acid domains specific to individual PKs. Thus, different substituents may contribute to preferential binding to particular PKs. The ability to select those compounds active at different ATP binding sites makes them useful in targeting any protein with such a site, including not only protein tyrosine kinases, but also serine/threonine kinases. Thus, such compounds have utility for *in vitro* assays on such proteins and for *in vivo* therapeutic effect through such proteins. For example, as mentioned above, certain types of cancer express both the *c-kit* receptor protein kinase and Stem Cell Factor (SCF) and this pairing could constitute an autocrine loop stimulating the growth of these cancerous cells. Therefore, inhibition of the *c-kit* protein kinase could disrupt this autocrine loop and thereby retard tumor growth and/or obliterate tumors via normal mechanisms of apoptosis.

Thus, in a first aspect, the invention provides a method for treating or preventing an abnormal condition in an organism. The abnormal condition is associated with an aberration in a signal transduction pathway mediated by an interaction between a *c-kit* kinase and a natural binding partner. The method involves administering to the organism a therapeutically effective amount of an indolinone compound. The indolinone compound modulates the interaction between the *c-kit* kinase and a natural binding partner. Therefore, promoting or disrupting (preferably disrupting) this

interaction is predicted to have therapeutic benefits to a given population of patients in need of such treatment. In a preferred embodiment, the amount of signaling through *c-kit* kinase is abnormal, and the compound promotes or disrupts the signaling.

5 The term "treating" refers to having a therapeutic effect and at least partially alleviating or abrogating an abnormal condition in the organism. The term "treating" preferably refers to ameliorating a symptom of the abnormal condition in a group of patients to whom the indolinone is administered relative to a control group that does not receive the indolinone. The effect of the treatment can be monitored by measuring a change or an absence of a change in cell phenotype, a change or an absence of a change
10 in cell proliferation, a change or an absence of a change in the catalytic activity of this *c-kit* protein kinase, and a change or an absence of a change in the interaction between this protein kinase and a natural binding partner. The term "treating" or "treatment" does not necessarily mean total cure. Any alleviation of any undesired symptom of the disease to any extent or the slowing down of the progress of the disease can be
15 considered treatment. Furthermore, treatment may include acts which may worsen the patient's overall feeling of well being or appearance. For example, the administration of chemotherapy in cancer patients which may leave the patients feeling "sicker" is still considered treatment.

The term "catalytic activity" used above, in the context of the invention, defines
20 the rate at which a protein kinase phosphorylates a substrate. Catalytic activity can be measured, for example, by determining the amount of a substrate converted to a product as a function of time. Phosphorylation of a substrate occurs at the active site of a protein kinase. The active site is normally a cavity in which the substrate binds to the protein kinase and is phosphorylated.

25 The term "substrate" as used above and herein refers to a molecule phosphorylated by a protein kinase. The substrate is preferably a peptide and more preferably a protein.

The term "preventing" refers to decreasing the probability that an organism contracts or develops an abnormal condition. The term "preventing" preferably refers
30 to reducing the percentage of individuals who develop the abnormal condition relative to a control group that does not undergo administration of an indolinone.

The term "abnormal condition" refers to a function in the cells or tissues of an organism that deviates from its normal functions in that organism. An abnormal condition can relate to cell proliferation, cell differentiation, or cell survival. Abnormal conditions include mastocytosis, the presence of one or more mast cell tumors, asthma, 5 allergy-associated chronic rhinitis, small cell lung cancer, non-small cell lung cancer, acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, colorectal carcinomas, gastric carcinomas, gastrointestinal stromal tumors, testicular cancers, glioblastomas, and astrocytomas. In a preferred embodiment, these abnormal conditions, such as mast cell tumors and 10 mastocytosis, arise in non-human organisms and may thus be prevented or treated during the practice of veterinary medicine.

Abnormal cell survival conditions relate to conditions in which programmed cell death (apoptosis) pathways are activated or abrogated. A number of protein kinases are associated with the apoptosis pathways. Aberrations in the function of any one of the 15 protein kinases could lead to cell immortality or premature cell death.

The term "function" as used in relation to a protein kinase above refers to the cellular role of a protein kinase, preferably a *c-kit* kinase. The protein kinase family includes members that regulate many steps in signaling cascades, including cascades controlling cell growth, migration, differentiation, gene expression, muscle contraction, 20 glucose metabolism, cellular protein synthesis, and regulation of the cell cycle. The "function" of a membrane receptor kinase usually is to transduce a signal from outside a cell's membrane to the interior of a cell. To accomplish this it may perform one or all of these other functions: bind a ligand, dimerize to another membrane receptor kinase, phosphorylate other proteins within the cell, bind other proteins within the cell, and 25 cause the localization of proteins within the cell.

The term "organism" relates to any living entity comprised of at least one cell. An organism can be as simple as one eukaryotic cell or as complex as a mammal. The organism is preferably a mammal, more preferably a human.

The term "mammal" refers preferably to such organisms as mice, rats, rabbits, 30 guinea pigs, sheep, and goats, more preferably to cats, dogs, monkeys, and apes. In

preferred embodiments, the abnormal condition associated with mammals may include mastocytosis, and the presence of one or more mast cell tumors.

The term “aberration,” refers to a protein kinase, *e.g.*, a *c-kit* kinase that is over- or under-expressed in an organism, mutated such that its catalytic activity is lower or
5 higher than wild-type protein kinase activity, mutated such that it can no longer interact with a natural binding partner, no longer functions in an autocrine loop within the cell, is no longer modified by another protein kinase or protein phosphatase, or no longer interacts with a natural binding partner. Preferably, the aberration involves excessive or deficient signaling upon interaction with a natural binding partner.

10 The term “signal transduction pathway” refers to the molecules that propagate an extracellular signal through the cell membrane to become an intracellular signal. This signal can then stimulate a cellular response. The polypeptide molecules involved in signal transduction processes include receptor and non-receptor protein tyrosine kinases, receptor and non-receptor protein phosphatases, proteins containing SRC
15 homology 2 and 3 domains, phosphotyrosine binding proteins (SRC homology 2 (SH2) and phosphotyrosine binding (PTB and PH) domain containing proteins), proline-rich binding proteins (SH3 domain containing proteins), GTPases, phosphodiesterases, phospholipases, prolyl isomerases, proteases, Ca^{2+} binding proteins, cAMP binding proteins, guanyl cyclases, adenylyl cyclases, NO generating proteins, nucleotide
20 exchange factors, and transcription factors.

The term “mediated” refers to involvement in the control or effect of the interaction between *c-kit* kinase and the natural binding partners on the aberration in the signal transduction pathway. Thus, the signal transduction pathway that has an aberration and is associated with the abnormal condition, contains a *c-kit* kinase in
25 interaction with a natural binding partner.

The “interaction” of a *c-kit* kinase molecule is the binding of that *c-kit* kinase molecule to a natural binding partner or molecule within the cell or the phosphorylation by a *c-kit* kinase molecule of another protein or molecule within the cell, or any other association of *c-kit* kinase within a cell. These interactions include non-covalent
30 interactions such as hydrogen bonding, Van der Waals interactions, hydrophobic interactions, and ionic bonding.

The term "*c-kit* kinase" refers to a membrane receptor protein tyrosine kinase which is preferably activated upon binding Stem Cell Factor (SCF) to its extracellular domain (Yarden *et al.*, 1987; Qiu *et al.*, 1988). The receptor tyrosine kinase *c-kit* kinase contains 5 immunoglobulin-like motifs in the extracellular domain and a cytoplasmic "split" kinase domain, Figure 1. The full length amino acid sequence of a *c-kit* kinase preferably is as set forth in Yarden, *et al.*, 1987, *EMBO J.* 11:3341-3351; and Qiu, *et al.*, 1988, *EMBO J* 7:1003-1011, which are incorporated by reference herein in their entirety, including any drawings. Mutant versions of *c-kit* kinase are encompassed by the term "*c-kit* kinase" and include those that fall into two classes: (1) having a single amino acid substitution at codon 816 of the human *c-kit* kinase, or its equivalent position in other species (Ma *et al.*, 1999, *J. Invest Dermatol* 112:165-170), and (2) those which have mutations involving the putative juxtamembrane α -helix of the protein (Ma, *et al.*, 1999, *J Biol Chem* 274:13399-13402). Both of these publications are incorporated by reference herein in their entirety, including any drawings.

The term "natural binding partner" refers to a polypeptide or compound such as ATP that binds to a protein kinase in cells. Natural binding partners can play a role in propagating a signal in a protein kinase signal transduction process. A change in the interaction between a protein kinase and a natural binding partner can manifest itself as an increased or decreased probability that the interaction forms, or an increased or decreased concentration of the protein kinase/natural binding partner complex.

A "therapeutically effective" amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. A "therapeutically effective amount," in reference to the treatment of a cancer refers to an amount sufficient to bring about one or more of the following results: reduce the size of the cancer, inhibit the metastasis of the cancer, inhibit the growth of the cancer, stop the growth of the cancer, relieve discomfort due to the cancer, or prolong the life of a patient inflicted with the cancer. A "therapeutically effective amount", in reference to the treatment of a cell proliferative disorder other than a cancer refers to an amount sufficient to bring about one or more of the following

results: inhibit the growth of cells causing the disorder, relieve discomfort due to the disorder, or prolong the life of a patient suffering from the disorder.


The term "indolinone" is used as that term is commonly understood in the art and includes a large subclass of substituted or unsubstituted compounds that are capable
5 of being synthesized from an aldehyde moiety and an oxindole moiety. In preferred embodiments, the indolinones included in the present method have the structures of Formulas I and II (see below), and more preferably are selected from Compounds One through Thirteen (see below).

Examples of representative indolinone compounds and the synthesis thereof, are
10 set forth in the following applications: (1) PCT application number US99/06468, filed March 26, 1999 by Fong, *et al.* and entitled METHODS OF MODULATING TYROSINE PROTEIN KINASE (Lyon & Lyon docket number 231/250 PCT), (2) U.S. Provisional Application No. 60/131,192, filed April 26, 1999 by Tang, *et al.* and entitled DIARYL INDOLINONE COMPOUNDS AS KINASE INHIBITORS (Lyon &
15 Lyon docket number 239/205), (3) U.S. Provisional Application No. 60/132,243, filed May 3, 1999 by Tang, *et al.* and entitled SYNTHESIS OF 4-SUBSTITUTED OXINDOLE AND INDOLINONE COMPOUNDS AND THEIR USE IN TREATMENT OF DISEASE (Lyon & Lyon docket number 231/251), (4) U.S. Application No. 09/283,657, filed April 1, 1999 by Tang, *et al.* and entitled METHODS
20 OF MODULATING TYROSINE PROTEIN KINASE FUNCTION WITH INDOLINONE COMPOUNDS (Lyon & Lyon docket number 241/180), and (5) U.S. Patent No. 5,792,783, issued August 11, 1998 by Tang *et al.*, entitled 3-HETEROARYL-2-INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE which are hereby incorporated by reference in their entirety including any
25 drawings.

Preferably, the compounds used in the invention have a structure set forth in Formula I,

(I)

5




wherein

- (a) Y is selected from the group consisting of oxygen, sulfur and nitrogen substituted with a hydrogen;
- 10 (b) R₁, R₂, R₃, and R₄ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂ NRR', SO₃ R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_n CO₂ R, and CONRR';
- (c) R₅ is selected from the group consisting of hydrogen, alkyl, alkoxy, aryl,
- 15 aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂ NRR', SO₃ R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_n CO₂ R, CONRR', a six-membered heteroaryl ring system containing 1 or 2 N, O, or S atoms; and a six-membered aryl ring system; and
- (c) R₆, and R₇ are each independently selected from the group consisting of
- 20 hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂ NRR', SO₃ R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_n CO₂ R, and CONRR', where R can be a wide variety of substituent groups.

More preferably, the compounds used in the invention have a structure set forth in Formula II,

(II)

5




wherein

- (a) Y is selected from the group consisting of sulfur and nitrogen substituted with a hydrogen;
- (b) R₁ is selected from the group consisting of hydrogen and methyl;
- (c) R₂ is selected from the group consisting of
- (i) hydrogen;
 - (ii) chlorine;
 - (iii) bromine;
 - (iv) a ketone of the formula -CO-CH₃,
 - (v) a sulfonamide of the formula -SO₂NH₂, or -SO₂NCH₃CH₃.
- (d) R₃, R₄, and R₅ are each independently selected from the group consisting of
- (i) hydrogen;
 - (ii) methyl;
 - (iii) a carboxylic acid of formula -(CH₂)₂-COOH; and
 - (iv) R₈ and R₉ taken together form a six-membered saturated carbon ring.


Most preferably, the compound is one of the following:

Compound One, below:




5

Compound Two, below:




10


Compound Three, below:




15 Compound Four, below:




Compound Five, below:




5 Compound Six, below:



10 Compound Seven, below:




Compound Eight, below:




15

Compound Nine, below:




5 Compound Ten, below




Compound Eleven, below:

10




Compound Twelve, below:

15




20

Compound Thirteen, below:




5 Compound Fourteen, below:




Compound Fifteen, below:

10



Compound Sixteen, below:




15

16

The term "oxindole" refers to an oxindole compound substituted with chemical substituents. Oxindole compounds are of the general structure shown in Formula III:

(III)



5

The term "substituted", in reference to the invention, refers to an oxindole compound that is derivatized with any number of chemical substituents.

The indolinone compounds of the invention preferably modulate the activity of the protein tyrosine kinase *in vitro*. These compounds preferably show positive results in one or more *in vitro* assays for an activity corresponding to treatment of the disease or disorder in question (such as the assays described in the Examples below). The protein tyrosine kinase which is modulated by the indolinone compounds of the invention is preferably the *c-kit* kinase. Examples of the procedures for and the results of such modulation are described in the Examples below.

15

The term "compound" means any identifiable molecule or a pharmaceutically acceptable salt, ester, amide, prodrug, isomer, or metabolite, thereof.

A "prodrug" refers to an agent which is converted into the parent drug *in vivo*. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water solubility is beneficial.

20

25

A further example of a prodrug might be a short polypeptide, for example, without limitation, a 2 - 10 amino acid polypeptide, bonded through a terminal amino

group to a carboxy group of a compound of this invention wherein the polypeptide is hydrolyzed or metabolized *in vivo* to release the active molecule.

The term “modulates” refers to altering the function of a protein kinase by increasing or decreasing the probability that a complex forms between a protein kinase and a natural binding partner. A modulator preferably increases the probability that such a complex forms between the protein kinase and the natural binding partner, more preferably increases or decreases the probability that a complex forms between the protein kinase and the natural binding partner depending on the concentration of the compound exposed to the protein kinase, and most preferably decreases the probability that a complex forms between the protein kinase and the natural binding partner. A modulator preferably activates the catalytic activity of a protein kinase, more preferably activates or inhibits the catalytic activity of a protein kinase depending on the concentration of the compound exposed to the protein kinase, or most preferably inhibits the catalytic activity of a protein kinase.

The term “complex” refers to an assembly of at least two molecules bound to one another. Signal transduction complexes often contain at least two protein molecules bound to one another.

The term “activates” refers to increasing the function of a protein kinase. The protein kinase function is preferably the interaction with a natural binding partner and most preferably catalytic activity.

The term “inhibit” refers to decreasing the function of a protein kinase. The protein kinase function is preferably the interaction with a natural binding partner and most preferably catalytic activity.

A protein kinase’s natural binding partner can bind to a protein kinase’s extracellular or intracellular region with high affinity. High affinity represents an equilibrium binding constant on the order of 10^{-6} M or less. In addition, a natural binding partner can also transiently interact with a protein kinase’s extracellular or intracellular region and chemically modify it. Protein kinase natural binding partners are chosen from a group that includes, but is not limited to, SRC homology 2 (SH2) or 3 (SH3) domains, other phosphoryl tyrosine binding (PTB) domains, guanine nucleotide exchange factors, protein phosphatases, other protein kinases, and compounds such as

ATP. Methods of determining changes in interactions between protein kinases and their natural binding partners are readily available in the art.

The term "related to" refers to a disease which has been shown to be accompanied by inappropriate *c-kit* kinase expression when compared to the same
5 undiseased tissue isolated from an organism. The inappropriate expression can be an elevation of normal activities, a depression of normal activities, or the presence of *c-kit* kinase activity where none is normally found.

The term "*in vitro*" refers to when the *c-kit* kinase enzyme is tested outside of a living organism with a compound useful for this invention whereby such compounds
10 are screened for efficaciousness. The term "*in vitro*" includes the use of tissue culture cells.

The term "promotes or disrupts the abnormal interaction" refers to a method that can be accomplished by administering a compound of the invention to cells or tissues in an organism. A compound can promote an interaction between a protein kinase and
15 natural binding partners by forming favorable interactions with multiple atoms at the complex interface. Alternatively, a compound can inhibit an interaction between a protein kinase and natural binding partners by compromising favorable interactions formed between atoms at the complex interface. In preferred embodiments, the promotion or disruption of an abnormal interaction refers to the compound of the
20 invention promoting a conformational change in one of the proteins.

In another aspect, the invention relates to synthesis of indolinone compounds described herein, in particular indolinones of Formula I, above, and especially Compounds One through Thirteen. The general scheme for the synthesis of representative indolinone compounds are set forth in the PCT publication US99/06468,
25 filed March 26, 1999 by Fong *et al.* and entitled METHODS OF MODULATING TYROSINE PROTEIN KINASE (Lyon & Lyon docket number 231/250 PCT) and the U.S. Patent No. 5,792,783, issued August 11, 1998 by Tang *et al.*, entitled 3-HETEROARYL-2-INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE which are hereby incorporated by reference in their entirety including any
30 drawings. Those skilled in the art know by reviewing the above reference which

oxindoles and which aldehydes are to be reacted under which suitable conditions to form the compounds of the present invention.

The invention also features a method of identifying indolinone compounds, or compounds such as a pharmaceutically acceptable salt, ester, amide, prodrug, isomer, or metabolite thereof, that modulate the function of *c-kit* kinase, comprising the following steps: (a) contacting cells expressing the *c-kit* kinase with the compound; and (b) monitoring an effect upon the cells. The effect upon the cells is preferably a change or an absence of a change in cell phenotype, more preferably it is a change or an absence of a change in cell proliferation, even more preferably it is a change or absence of a change in the catalytic activity of the *c-kit* kinase, and most preferably it is a change or absence of a change in the interaction between the *c-kit* kinase with a natural binding partner, as described herein.

The term “monitoring” refers to observing the effect of adding the compound to the cells of the method. The “monitoring” can be effected by comparing test cells with control cells.

The term “effect” describes a change or an absence of a change in cell phenotype or cell proliferation. “Effect” can also describe a change or an absence of a change in the catalytic activity of the pro *c-kit* kinase. “Effect” can also describe a change or an absence of a change in an interaction between the *c-kit* kinase and a natural binding partner.

The term “cell phenotype” refers to the outward appearance of a cell or tissue or the function of the cell or tissue. Examples of cell phenotype are cell size (reduction or enlargement), cell proliferation (increased or decreased numbers of cells), cell differentiation (a change or absence of a change in cell shape, cell function, or differences in protein expression), cell survival, apoptosis (cell death), or the utilization of a metabolic nutrient (*e.g.*, glucose uptake). Changes or the absence of changes in cell phenotype are readily measured by techniques known in the art.

In a preferred embodiment, the invention features a method for identifying the indolinones of the invention, comprising the following steps: (a) lysing the cells to render a lysate comprising *c-kit* kinase; (b) adsorbing the *c-kit* kinase to an antibody; (c) incubating the adsorbed *c-kit* kinase with a substrate or substrates; and (d) adsorbing a

detecting antibody to the *c-kit* kinase. The effect upon the kinases is then monitored and the step of monitoring the effect on the kinases comprises measuring the phosphate concentration incorporated into *c-kit* kinase.

5 The term "antibody" refers to an antibody (*e.g.*, a monoclonal or polyclonal antibody), or antibody fragment, having specific binding affinity to *c-kit* kinase or its fragment or to phosphotyrosine.

By "specific binding affinity" is meant that the antibody binds to target (*c-kit* kinase) polypeptides with greater affinity than it binds to other polypeptides under specified conditions. Antibodies having specific binding affinity to a *c-kit* kinase may
10 be used in methods for detecting the presence and/or amount of a *c-kit* kinase in a sample by contacting the sample with the antibody under conditions such that an immunocomplex forms and detecting the presence and/or amount of the antibody conjugated to the *c-kit* kinase. Diagnostic kits for performing such methods may be constructed to include a first container containing the antibody and a second container
15 having a conjugate of a binding partner of the antibody and a label, such as, for example, a radioisotope. The diagnostic kit may also include notification of an FDA approved use and instructions therefor.

The term "polyclonal" refers to antibodies that are heterogenous populations of antibody molecules derived from the sera of animals immunized with an antigen or an
20 antigenic functional derivative thereof. For the production of polyclonal antibodies, various host animals may be immunized by injection with the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species.

"Monoclonal antibodies" are substantially homogenous populations of
25 antibodies to a particular antigen. They may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. Monoclonal antibodies may be obtained by methods known to those skilled in the art. See, for example, Kohler, et al., *Nature* 256:495-497 (1975), and U.S. Patent No. 4,376,110.

30 The term "antibody fragment" refers to a portion of an antibody, often the hypervariable region and portions of the surrounding heavy and light chains, that

displays specific binding affinity for a particular molecule. A hypervariable region is a portion of an antibody that physically binds to the polypeptide target.

The summary of the invention described above is non-limiting and other features and advantages of the invention will be apparent from the following description
5 of the preferred embodiments, and from the claims.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a schematic diagram showing the 5 immunoglobulin-like motifs in the extracellular domain and a cytoplasmic "split" kinase domain of *c-kit* kinase. The
10 half-loops represent the immunoglobulin-like motifs, and the shaded boxes represent the conserved kinase region of the receptors.

Figure 2 shows the effects of indolinone derivatives on the activity of *c-kit* kinase as measured by ELISA as described in Example 1 in the experimental section.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to methods, compounds and compositions capable of regulating and/or modulating cellular signal transduction and, in preferred
15 embodiments, *c-kit* kinase signal transduction.

20 Receptor kinase-mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein kinase activity, and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that
25 facilitate the appropriate cellular response (*e.g.*, cell division, metabolic effects to the extracellular microenvironment). *See*, Schlessinger and Ullrich, 1992, *Neuron* 9:303-391.

Kinase signal transduction results in, among other responses, cell proliferation, differentiation and metabolism. Abnormal cell proliferation may result in a wide array
30 of disorders and diseases, including the development of neoplasia such as carcinoma, sarcoma, leukemia, glioblastoma, hemangioma, psoriasis, arteriosclerosis, arthritis and

diabetic retinopathy (or other disorders related to uncontrolled angiogenesis and/or vasculogenesis).

This invention is therefore directed to methods, compounds, and compositions which regulate, modulate and/or inhibit kinase signal transduction by affecting the enzymatic activity of receptor kinases and interfering with the signal transduced by such proteins. More particularly, the present invention is directed to methods, compounds and compositions which regulate, modulate and/or inhibit the *c-kit* receptor tyrosine kinase and/or other kinase mediated signal transduction pathways as a therapeutic approach to cure many kinds of solid tumors and leukemias, including but not limited to carcinoma, sarcoma, erythroblastoma, glioblastoma, meningioma, astrocytoma, melanoma and myoblastoma. Indications may include, but are not limited to lung cancers, including both small cell lung cancers and non-small cell lung cancers, brain cancers, bladder cancers, ovarian cancers, gastric cancers, pancreas cancers, colon cancers, blood cancers, and bone cancers. The present invention is also directed to the treatment and/or prevention of those conditions characterized by the overexpression of mast cells, or the inappropriate up-regulation of mast cells, including, but not limited to, mastocytosis, and allergy-associated chronic rhinitis, inflammation and asthma. These conditions are described in greater detail below.

I. Target Diseases to be Treated by the Compounds of the Invention.

The compounds described herein are useful for treating disorders related to unregulated kinase signal transduction, including cell proliferative disorders, fibrotic disorders and metabolic disorders. Cell proliferative disorders which can be treated or further studied by the present invention include cancers, and mast cell proliferative disorders.

PTKs have been associated with such cell proliferative disorders. For example, some members of the receptor tyrosine kinase (RTK) family have been associated with the development of cancer. Some of these receptors, like the EGFR (Tuzi, *et al.*, 1991, *Br. J. Cancer* 63:227-233; Torp, *et al.*, 1992, *APMIS* 100:713-719) HER2/*neu* (Slamon, *et al.*, 1989, *Science* 244:707-712) and the PDGF-R (Kumabe, *et al.*, 1992, *Oncogene* 7:627-633) are overexpressed in many tumors and/or persistently activated by autocrine loops. In fact, in the most common and severe cancers these receptor overexpressions

(Akbasak and Suner-Akbasak, *et al.*, 1992, *J. Neurol. Sci.* 111:119-133; Dickson, *et al.*, 1992, *Cancer Treatment Res.* 61:249-273; Korc, *et al.*, 1992, *J. Clin. Invest.* 90:1352-1360) and autocrine loops (Lee and Donoghue, 1992, *J. Cell. Biol.* 118:1057-1070; Korc, *et al.*, *supra*; Akbasak and Suner-Akbasak, *et al.*, *supra*) have been demonstrated.

5 For example, the EGFR receptor has been associated with squamous cell carcinoma, astrocytoma, glioblastoma, head and neck cancer, lung cancer and bladder cancer. HER2 has been associated with breast, ovarian, gastric, lung, pancreas and bladder cancer. The PDGF-R has been associated with glioblastoma, lung, ovarian, melanoma and prostate cancer.

10 The *c-kit* receptor kinase has been associated with such cell proliferative disorders. For example, the *c-kit* kinase receptor has been found to be aberrantly expressed in over half the SCLC cells studied along with its ligand SCF (Hibi, *et al.*, 1991, *Oncogene* 6:2291-2296). Potentially, inhibition of the *c-kit* kinase will improve the long term survival of patients with SCLC.

15 The presence of *c-kit* RTK and/or SCF has also been associated with other types of cancers, as described below. The association between abnormalities in RTKs and disease are not restricted to cancer, however. For example, the *c-kit* Receptor Kinase has been associated with immune diseases such as mastocytosis, asthmas and chronic rhinitis. Excessive activation of *c-kit* might be associated with diseases resulting from
20 an over-abundance of mast cells. Mastocytosis is the term used to describe a heterogeneous series of disorders characterized by excessive mast cell proliferation (Metcalf, 1991, *J. Invest. Derm* 93:2S-4S; Valent, 1996, *Wein/Klin Wochenschr* 108:385-397; and Golkar, *et al.*, 1997, *Lancet* 349:1379-1385). Elevated *c-kit* expression was reported on mast cells from patients with aggressive mastocytosis, but
25 not on mast cells from patients with indolent mastocytosis (Nagata, *et al.*, 1998, *Leukemia* 12:175-181).

Additionally, mast cells and eosinophils represent key cells involved in allergy, inflammation and asthma (Thomas, *et al.*, 1996, *Gen. Pharmacol* 27:593-597; Metcalfe, *et al.*, 1997, *Physiol Rev* 77:1033-1079; Holgate, 1997, *CIBA Found. Symp.*; Naclerio, *et al.*, 1997, *JAMA* 278:1842-1848 and Costa, *et al.*, 1997, *JAMA* 278:1815-1822).
30 SCF, and hence *c-kit*, directly and indirectly regulates activation of both mast cells and

eosinophils, thereby influencing the primary cells involved in allergy and asthma through multiple mechanisms. Because of this mutual regulation of mast cell and eosinophil function, and the role that SCF can play in this regulation, inhibition of *c-kit* Kinase may provide a means to treat allergy-associated chronic rhinitis, inflammation
5 and asthma.

II. *c-kit* Kinase

The *c-kit* kinase plays a critical role in the development of melanocytes, mast, germ and hematopoietic cells. The protein encoded by the *Sl* locus has been called *kit* ligand (KL), stem cell factor (SCF) or mast cell growth factor (MGF), based on its
10 biological properties used to identify it (reviewed in Tsujimura, 1996, *Pathol Int* 46:933-938; Loveland, *et al.*, 1997, *J. Endocrinol* 153:337-344; Vliagoftis, *et al.*, 1997, *Clin Immunol* 100:435-440; Broudy, 1997, *Blood* 90:1345-1364; Pignon, 1997, *Hematol Cell Ther* 39:114-116; and Lyman, *et al.*, 1998, *Blood* 91:1101-1134.). For simplicity, we will use SCF to designate the ligand for the *c-kit* RTK. SCF is
15 synthesized as a transmembrane protein with a molecular weight of 220 or 248 Dalton, depending on alternative splicing of the mRNA to encode exon 6. The larger protein can be proteolytically cleaved to form a soluble, glycosylated protein which noncovalently dimerizes. Both the soluble and membrane-bound forms of SCF can bind to and activate *c-kit*. For example, in the skin, SCF is predominantly expressed by
20 fibroblasts, keratinocytes, and endothelial cells, which modulate the activity of melanocytes and mast cells expressing *c-kit*. In bone, marrow stromal cells express SCF and regulate hematopoiesis of *c-kit* expressing stem cells. In the gastrointestinal tract, intestinal epithelial cells express SCF and affect the interstitial cells of Cajal and intraepithelial lymphocytes. In the testis, sertoli cells and granulosa cells express SCF
25 which regulates spermatogenesis by interaction with *c-kit* on germ cells.

a. Target Malignancies of the Present Invention Involving *c-kit* Kinase and/or SCF

Aberrant expression and/or activation of *c-kit* has been implicated in a variety of tumors. Evidence for a contribution of *c-kit* to neoplastic pathology includes its
30 association with leukemias and mast cell tumors, small cell lung cancer, testicular cancer, and some cancers of the gastrointestinal tract and central nervous system (see

below). In addition, *c-kit* has been implicated in playing a role in carcinogenesis of the female genital tract (Inoue, *et al.*, 1994, *Cancer Res.* 54(11):3049-3053), sarcomas of neuroectodermal origin (Ricotti, *et al.*, 1998, *Blood* 91:2397-2405), and Schwann cell neoplasia associated with neurofibromatosis (Ryan, *et al.*, 1994, *J. Neuro. Res.* 37:415-432).

Leukemias: SCF binding to the *c-kit* RTK protects hematopoietic stem and progenitor cells from apoptosis (Lee, *et al.*, 1997, *J. Immunol.* 159:3211-3219), thereby contributing to colony formation and hematopoiesis. Expression of *c-kit* is frequently observed in acute myelocytic leukemia (AML), but is less common in acute lymphocytic leukemia (ALL) (for reviews, see Sperling, *et al.*, 1997, *Haemat* 82:617-621; Escribano, *et al.*, 1998, *Leuk. Lymph.* 30:459-466). Although *c-kit* is expressed in the majority of AML cells, its expression does not appear to be prognostic of disease progression (Sperling, *et al.*, 1997, *Haemat* 82:617-621). However, SCF protected AML cells from apoptosis induced by chemotherapeutic agents (Hassan, *et al.*, 1996, *Acta. Hem.* 95:257-262). Inhibition of *c-kit* by the present invention will enhance the efficacy of these agents and may induce apoptosis of AML cells.

The clonal growth of cells from patients with myelodysplastic syndrome (Sawada, *et al.*, 1996, *Blood* 88:319-327) or chronic myelogenous leukemia (CML) (Sawai, *et al.*, 1996, *Exp. Hem.* 2:116-122) was found to be significantly enhanced by SCF in combination with other cytokines. CML is characterized by expansion of Philadelphia chromosome positive cells of the marrow (Verfaillie, *et al.*, 1998, *Leuk.* 12:136-138), which appears to primarily result from inhibition of apoptotic death (Jones, 1997, *Curr. Opin. Onc.* 9:3-7). The product of the Philadelphia chromosome, p210^{BCR-ABL}, has been reported to mediate inhibition of apoptosis (Bedi, *et al.*, 1995, *Blood* 86:1148-1158). Since p210^{BCR-ABL} and the *c-kit* RTK both inhibit apoptosis and p62^{dok} has been suggested as a substrate (Carpino, *et al.*, 1997, *Cell* 88:197-204), it is possible that clonal expansion mediated by these kinases occurs through a common signaling pathway. However, *c-kit* has also been reported to interact directly with p210^{BCR-ABL} (Hallek, *et al.*, 1996, *Brit. J. Haem.* 94:5-16), which suggests that *c-kit* may have a more causative role in CML pathology. Therefore, inhibition of *c-kit* kinase will prove useful in the treatment of the above disorders.

Gastrointestinal cancers: Normal colorectal mucosa does not express *c-kit* (Bellone, *et al.*, 1997, *J. Cell Physiol.* 172:1-11). However, *c-kit* is frequently expressed in colorectal carcinoma (Bellone, *et al.*, 1997, *J. Cell Physiol.* 172:1-11), and autocrine loops of SCF and *c-kit* have been observed in several colon carcinoma cell lines (Toyota, *et al.*, 1993, *Turn Biol* 14:295-302; Lahm, *et al.*, 1995, *Cell Growth & Differ* 6:1111-1118; Bellone, *et al.*, 1997, *J. Cell Physiol.* 172:1-11). Furthermore, disruption of the autocrine loop by the use of neutralizing antibodies (Lahm, *et al.*, 1995, *Cell Growth & Differ.* 6:1111-1118) and downregulation of *c-kit* and/or SCF significantly inhibits cell proliferation (Lahm, *et al.*, 1995, *Cell Growth & Differ* 6:1111-1118; Bellone, *et al.*, 1997, *J. Cell Physiol.* 172:1-11).

SCF/*c-kit* autocrine loops have been observed in gastric carcinoma cell lines (Turner, *et al.*, 1992, *Blood* 80:374-381; Hassan, *et al.*, 1998, *Digest. Dis. Science* 43:8-14), and constitutive *c-kit* activation also appears to be important for gastrointestinal stromal tumors (GISTs). GISTs are the most common mesenchymal tumor of the digestive system. More than 90% of GISTs express *c-kit*, which is consistent with the putative origin of these tumor cells from interstitial cells of Cajal (ICCs) (Hirota, *et al.*, 1998, *Science* 279:577-580). ICCs are thought to regulate contraction of the gastrointestinal tract, and patients lacking *c-kit* in their ICCs exhibited a myopathic form of chronic idiopathic intestinal pseudo-obstruction (Isozaki, *et al.*, 1997, *Amer. J. of Gast.* 9 332-334). The *c-kit* expressed in GISTs from several different patients was observed to have mutations in the intracellular juxtamembrane domain leading to constitutive activation of this RTK (Hirota, *et al.*, 1998, *Science* 279:577-580). Hence, inhibition of *c-kit* kinase will be an efficacious means for the treatment of these cancers.

Testicular cancers: Male germ cell tumors have been histologically categorized into seminomas, which retain germ cell characteristics, and nonseminomas which can display characteristics of embryonal differentiation. Both seminomas and nonseminomas are thought to initiate from a preinvasive stage designated carcinoma *in situ* (CIS) (Murty, *et al.*, 1998, *Sem. Oncol.* 25:133-144). Both *c-kit* and SCF have been reported to be essential for normal gonadal development during embryogenesis (Loveland, *et al.*, 1997, *J. Endocrinol* 153:337-344). Loss of either the receptor or the ligand resulted in animals devoid of germ cells. In postnatal testes, *c-kit* has been found

to be expressed in Leydig cells and spermatogonia, while SCF was expressed in Sertoli cells (Loveland, *et al.*, 1997, *J. Endocrinol* 153:337-344). Testicular tumors develop from Leydig cells with high frequency in transgenic mice expressing human papilloma virus 16 (HPV16) E6 and E7 oncogenes (Kondoh, *et al.*, 1991, *J. Virol.* 65:3335-3339; 5 Kondoh, *et al.*, 1994, *J. Urol.* 152:2151-2154). These tumors express both *c-kit* and SCF, and an autocrine loop may contribute to the tumorigenesis (Kondoh, *et al.*, 1995, *Oncogene* 10:341-347) associated with cellular loss of functional p53 and the retinoblastoma gene product by association with E6 and E7 (Dyson, *et al.*, 1989, *Science* 243:934-937; Werness, *et al.*, 1990, *Science* 248:76-79; Scheffner, *et al.*, 1990, 10 *Cell* 63:1129-1136). Defective signaling mutants of SCF (Kondoh, *et al.*, 1995, *Oncogene* 10:341-347) or *c-kit* (Li, *et al.*, 1996, *Canc. Res.* 56:4343-4346) inhibited formation of testicular tumors in mice expressing HPV16 E6 and E7. The *c-kit* kinase activation is pivotal to tumorigenesis in these animals and thus modulation of the *c-kit* kinase pathway by the present invention will prevent or treat such disorders.

15 Expression of *c-kit* on germ cell tumors shows that the receptor is expressed by the majority of carcinomas *in situ* and seminomas, but *c-kit* is expressed in only a minority of nonseminomas (Strohmeyer, *et al.*, 1991, *Canc. Res.* 51:1811-1816; Rajpert-de Meyts, *et al.*, 1994, *Int. J. Androl.* 17:85-92; Izquierdo, *et al.*, 1995, *J. Pathol.* 177:253-258; Strohmeyer, *et al.*, 1995, *J. Urol.* 153:511-515; Bokenmeyer, *et al.*, 1996, *J. Cance. Res. Clin. Oncol.* 122:301-306; Sandlow, *et al.*, 1996, *J. Androl.* 20 17:403-408). Therefore, inhibition of *c-kit* kinase will provide a valuable new means for treating these disorders.

CNS cancers: SCF and *c-kit* are expressed throughout the CNS of developing rodents, and the pattern of expression suggests a role in growth, migration and 25 differentiation of neuroectodermal cells. Expression of both receptor and ligand have also been reported in the adult brain (Hamel, *et al.*, 1997, *J. Neuro-Onc.* 35:327-333). Expression of *c-kit* has also been observed in normal human brain tissue (Tada, *et al.* 1994, *J. Neuro* 80:1063-1073). Glioblastoma and astrocytoma, which define the majority of intracranial tumors, arise from neoplastic transformation of astrocytes 30 (Levin, *et al.*, 1997, *Principles & Practice of Oncology*:2022-2082). Expression of *c-kit* has been observed in glioblastoma cell lines and tissues (Berdel, *et al.*, 1992, *Canc. Res.*

52:3498-3502; Tada, *et al.* 1994, *J. Neuro* 80:1063-1073; Stanulla, *et al.*, 1995, *Act Neuropath* 89:158-165).

The association of *c-kit* with astrocytoma pathology is less clear. Reports of expression of *c-kit* in normal astrocytes have been made (Natali, *et al.*, 1992, *Int. J. Canc.* 52:197-201), (Tada, *et al.* 1994, *J. Neuro* 80:1063-1073), while others report it is not expressed (Kristt, *et al.*, 1993, *Neuro.* 33:106-115). In the latter case, high levels of *c-kit* expression in high grade tumors were observed (Kristt, *et al.*, 1993, *Neuro.* 33:106-115), while the former groups were unable to detect any expression in astrocytomas. In addition, contradictory reports of *c-kit* and SCF expression in neuroblastomas also exist. One study found that neuroblastoma cell lines often express SCF, but rarely express *c-kit*. In primary tumors, *c-kit* was detected in about 8% of neuroblastomas, while SCF was found in 18% of tumors (Beck, *et al.*, 1995, *Blood* 86:3132-3138). In contrast, other studies (Cohen, *et al.*, 1994, *Blood* 84:3465-3472) have reported that all 14 neuroblastoma cell lines examined contained *c-kit*/SCF autocrine loops, and expression of both the receptor and ligand were observed in 45% of tumor samples examined. In two cell lines, anti- *c-kit* antibodies inhibited cell proliferation, suggesting that the SCF/*c-kit* autocrine loop contributed to growth (Cohen, *et al.*, 1994, *Blood* 84:3465-3472). Hence, *c-kit* kinase inhibitors will prove therapeutically useful as a means to treat these cancers.

b. Target Mast Cell Diseases Involving *c-kit* Kinase and/or SCF to be Treated/Prevented by the Present Invention.

Mastocytosis: As mentioned above, SCF (also known as mast cell growth factor) stimulation of *c-kit* has been reported to be essential for the growth and development of mast cells (Hamel, *et al.*, 1997, *J. Neuro-Onc.* 35:327-333; Kitamura, *et al.*, 1995, *Int. Arch. Aller. Immunol.* 107:54-56). Mice with mutations of *c-kit* that attenuate its signaling activity have exhibited significantly fewer mast cells in their skin (Tsujimura, 1996, *Pathol Int* 46:933-938). Excessive activation of *c-kit* might be associated with diseases resulting from an over abundance of mast cells.

Mastocytosis is the term used to describe a heterogeneous series of disorders characterized by excessive mast cell proliferation (Metcalf, 1991, *J. Invest. Derm* 93:2S-4S; Valent, 1996; Golkar, *et al.*, 1997, *Lancet* 349:1379-1385). Mastocytosis is

limited to the skin in the majority of patients, but can involve other organs in 15-20% of patients (Valent, 1996, *Wein/Klin Wochenschr* 108:385-397; Golkar, *et al.*, 1997, *Lancet* 349:1379-1385). Even among patients with systemic mastocytosis, the disease can range from having a relatively benign prognosis to aggressive mastocytosis and mast cell leukemia. (Valent, 1996, *Wein/Klin Wochenschr* 108:385-397; Golkar, *et al.*, 1997, *Lancet* 349:1379-1385). *c-kit* has been observed on malignant mast cells from canine mast cell tumors (London, *et al.*, 1996, *J. Compar. Pathol.* 115:399-414), as well as on mast cells from patients with aggressive systemic mastocytosis (Baghestanian, *et al.*, 1996, *Leuk.* 116-122; Castells, *et al.*, 1996, *J. Aller. Clin. Immunol.* 98:831-840).

Elevated *c-kit* expression was reported on mast cells from patients with aggressive mastocytosis, but not on mast cells from patients with indolent mastocytosis (Nagata, *et al.*, 1998, *Mastocytosis Leuk* 12:175-181). SCF has been shown to be expressed on stromal cells as a membrane-bound protein, and its expression can be induced by fibrogenic growth factors such as PDGF (Hiragun, *et al.* 1998). It has also been shown to be expressed on keratinocytes as a membrane-bound protein in normal skin. However, in the skin of patients with mastocytosis, an increased amount of soluble SCF has been observed (Longley, *et al.*, 1993, *New Engl. J. Med.* 328:1302-1307).

Mast cell chymase has been reported to cleave membrane-associated SCF to a soluble and biologically active form. This mast cell-mediated process could serve to generate a feedback loop to enhance mast cell proliferation and function (Longley, *et al.*, 1997, *Proc. Natl. Acad. Sci.* 94:9017-9021), and may be important for the etiology of mastocytosis. Transgenic mice overexpressing a form of SCF that could not be proteolytically released from keratinocytes did not develop mastocytosis, while similar animals expressing normal SCF in keratinocytes exhibited a phenotype resembling human cutaneous mastocytosis (Kunisada, *et al.*, 1998, *J. Exp. Med.* 187:1565-1573). Formation of large amounts of soluble SCF can contribute to the pathology associated with mastocytosis in some patients and the present invention can treat or prevent such disorders by modulating the interaction between SCF and *c-kit* kinase. Several different mutations of the *c-kit* RTK that resulted in constitutive kinase activity have been found in human and rodent mast cell tumor cell lines (Furitsu, *et al.*, 1993, *J. Clin. Invest.*

92:1736-1744; Tsujimura, *et al.*, 1994, *Blood* 9:2619-2626; Tsujimura, *et al.*, 1995, *Int. Arch. Aller. Immunol* 106:377-385; Tsujimura, 1996, *Pathol Int* 46:933-938). In addition, activating mutations of the *c-kit* gene have been observed in peripheral mononuclear cells isolated from patients with mastocytosis and associated hematologic disorders (Nagata, *et al.*, 1998, *Mastocytosis Leuk* 12:175-181), and in mast cells from a patient with urticaria pigmentosa and aggressive mastocytosis (Longley, *et al.*, 1996, *Nat. Gen.* 12:312-314). Inhibition of *c-kit* kinase will therefore prove to have an excellent therapeutic role in the treatment of these disorders.

In some patients, activating mutations of the *c-kit* RTK may be responsible for the pathogenesis of the disease and these patients can be treated, or their diseases prevented, by modulation of the SCF interaction with *c-kit* kinase. SCF activation of *c-kit* as been shown to prevent mast cell apoptosis which may be critical for maintaining cutaneous mast cell homeostasis (Iemura, *et al.*, 1994, *Amer. J. Pathol* 144:321-328; Yee, *et al.*, 1994, *J. Exp. Med.* 179:1777-1787; Mekori, *et al.*, 1994, *J. Immunol* 153:2194-2203; Mekori, *et al.*, 1995, *Int. Arch. Allergy Immunol.* 107:137-138). Inhibition of mast cell apoptosis could lead to the mast cell accumulation associated with mastocytosis. Thus, observation of *c-kit* activation resulting from overexpression of the receptor, excessive formation of soluble SCF, or mutations of the *c-kit* gene that constitutively activate its kinase, provides a rationale that inhibition of the kinase activity of *c-kit* will decrease the number of mast cells and provide benefit for patients with mastocytosis.

Asthma & Allergy: Mast cells and eosinophils represent key cells in parasitic infection, allergy, inflammation, and asthma (Thomas, *et al.*, 1996, *Gen. Pharmacol* 27:593-597; Metcalfe, *et al.*, 1997, *Physiol Rev* 77:1033-1079; Holgate, 1997, *CIBA Found. Symp.*; Naclerio, *et al.*, 1997, *JAMA* 278:1842-1848; Costa, *et al.*, 1997, *JAMA* 278:1815-1822). SCF has been shown to be essential for mast cell development, survival and growth (Kitamura, *et al.*, 1995, *Int. Arch. Aller. Immunol.* 107:54-56; Metcalfe, *et al.*, 1997, *Physiol Rev* 77:1033-1079). In addition, SCF cooperates with the eosinophil-specific regulator, IL-5, to increase the development of eosinophil progenitors (Metcalf, *et al.*, 1998, *Proc. Natl. Acad. Sci., USA* 95:6408-6412). SCF has also been reported to induce mast cells to secrete factors (Okayama, *et al.*, 1997, *Int.*

Arch. Aller. Immunol. 114:75-77; Okayama, *et al.*, 1998, *Eur. J. Immunol.* 28:708-715) that promote the survival of eosinophils (Kay, *et al.*, 1997, *Int. Arch. Aller. Immunol.* 113:196-199), which may contribute to chronic, eosinophil-mediated inflammation (Okayama, *et al.*, 1997, *Int. Arch. Aller. Immunol.* 114:75-77; Okayama, *et al.*, 1998, *Eur. J. Immunol.* 28:708-715). In this regard, SCF directly and indirectly regulates activation of both mast cells and eosinophils.

SCF induces mediator release from mast cells, as well as priming these cells for IgE-induced degranulation (Columbo, *et al.*, 1992, *J. Immunol* 149:599-602) and sensitizing their responsiveness to eosinophil-derived granule major basic protein (Furuta, *et al.*, 1998, *Blood* 92:1055-1061). Among the factors released by activated mast cells are IL-5, GM-CSF and TNF- α , which influence eosinophil protein secretion (Okayama, *et al.*, 1997, *Int. Arch. Aller. Immunol.* 114:75-77; Okayama, *et al.*, 1998, *Eur. J. Immunol.* 28:708-715). In addition to inducing histamine release from mast cells (Luckacs, *et al.*, 1996, *J. Immunol.* 156:3945-3951; Hogaboam, *et al.*, 1998, *J. Immunol.* 160:6166-6171), SCF promotes the mast cell production of the eosinophil chemotactic factor, eotaxin (Hogaboam, *et al.*, 1998, *J. Immunol.* 160:6166-6171), and eosinophil infiltration (Luckacs, *et al.*, 1996, *J. Immunol.* 156:3945-3951).

SCF also directly influences the adhesion of both mast cells (Dastyh, *et al.*, 1994, *J. Immunol.* 152:213-219; Kinashi, *et al.*, 1994, *Blood* 83:1033-1038) and eosinophils (Yuan, *et al.*, 1997, *J. Exp. Med.* 186:313-323), which in turn, regulates tissue infiltration. Thus, SCF can influence the primary cells involved in allergy and asthma through multiple mechanisms. Currently, corticosteroids are the most effective treatment for chronic rhinitis and inflammation associated with allergy (Naclerio, *et al.*, 1997, *JAMA* 278:1842-1848; Meltzer, 1997, *Aller.* 52:33-40). These agents work through multiple mechanisms including reduction of circulating and infiltrating mast cells and eosinophils, and diminished survival of eosinophils associated with inhibition of cytokine production (Meltzer, 1997, *Aller.* 52:33-40). Steroids have also been reported to inhibit the expression of SCF by fibroblasts and resident connective tissue cells, which leads to diminished mast cell survival (Finotto, *et al.*, 1997, *J. Clin. Invest.* 99 1721-1728). Because of the mutual regulation of mast cell and eosinophil function,

and the role that SCF can play in this regulation, inhibition of *c-kit* kinase will provide a means to treat allergy-associated chronic rhinitis, inflammation and asthma.

c. Identification of Agonists and Antagonists to the *c-kit* Receptor

In view of the deduced importance of RTKs in the control, regulation and modulation of endothelial cell proliferation and potentially carcinogenesis, many attempts have been made to identify RTK "inhibitors" using a variety of approaches. These include the use of mutant ligands (U.S. Patent No. 4,966,849); soluble receptors and antibodies (Application No. WO 94/10202; Kendall and Thomas, 1994, *Proc. Natl. Acad. Sci. USA* 90:10705-10709; Kim, *et al.*, 1993, *Nature* 362:841-844); and RNA ligands (Jellinek, *et al.*, 1994, *Biochemistry* 33:10450-10456).

Furthermore, kinase inhibitors (WO 94/03427; WO 92/21660; WO 91/15495; WO 94/14808; U.S. Patent No. 5,330,992; Mariani, *et al.*, 1994, *Proc. Am. Assoc. Cancer Res.* 35:2268), and inhibitors acting on receptor kinase signal transduction pathways, such as protein kinase C inhibitors have been identified (Schuchter, *et al.*, 1991, *Cancer Res.* 51:682-687); Takano, *et al.*, 1993, *Mol. Bio. Cell* 4:358A; Kinsella, *et al.*, 1992, *Exp. Cell Res.* 199:56-62; Wright, *et al.*, 1992, *J. Cellular Phys.* 152:448-57).

More recently, attempts have been made to identify small molecules which act as kinase inhibitors for use in the treatment of cancer. Consequently, there is an unmet need for the identification and generation of effective small compounds which selectively inhibit the signal transduction of the *c-kit* RTK in order to effectively and specifically suppress this autocrine loop.

Some of the compounds of the present invention demonstrate excellent activity in biological assays and thus these compounds and related compounds are expected to be effective in treating *c-kit* RTK-related disorders such as those described above. Additionally, the assays and conditions described herein can be utilized to identify further modulators of *c-kit* kinase functions.

III. Biological Activity of the Compounds of the Invention

The indolinone compounds of the present invention were tested for their ability to inhibit most of protein kinase activity. The biological assays and results of these inhibition studies are reported herein. The methods used to measure indolinone

compound modulation of protein kinase function are similar to those described in International Publication No. WO 98/07695, published March 26, 1998, by Tang *et al.*, and entitled "INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR THE TREATMENT OF DISEASE," and U.S. Patent No. 5,792,783, issued August 11, 1998 by Tang *et al.*, entitled 3-HETEROARYL-2-INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE with respect to the high throughput aspect of the method. The WO 98/07695 publication is incorporated herein by reference in its entirety, including any drawings.

IV. Pharmaceutical Formulations and Routes of Administration

The compounds described herein can be administered to a human patient *per se*, or in pharmaceutical compositions where they are mixed with other active ingredients, as in combination therapy, or suitable carriers or excipient(s). Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition.

a) Routes of Administration

Suitable routes of administration may, for example, include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.

Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a solid tumor, often in a depot or sustained release formulation.

Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with tumor-specific antibody. The liposomes will be targeted to and taken up selectively by the tumor.

b) Composition/Formulation

The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper
5 formulation is dependent upon the route of administration chosen.

For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such
10 penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral
15 ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by mixing one or more solid excipients with one or more compounds of the invention, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose,
20 mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium
25 alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may
30 be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, *e.g.*, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection

suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

5 Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

10 In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or
15 ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be the VPD co-
20 solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:D5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration.
25 Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of Polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol,
30 *e.g.*, polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.

Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days.

Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

Many of the PTK modulating compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

c) Effective Dosage.

Pharmaceutical compositions suitable for use in the present invention include compositions where the active ingredients are contained in an amount effective to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

For any compound used in the methods of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC_{50} as determined in cell culture (*i.e.*, the concentration of the test compound which achieves a half-maximal inhibition of the PTK activity). Such information can be used to more accurately determine useful doses in humans.

Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio
5 between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD₅₀ and ED₅₀. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the
10 ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See *e.g.*, Fingl, *et al.*, 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p.1).

15 Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the kinase modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from *in vitro* data; *e.g.*, the concentration necessary to achieve 50-90% inhibition of the kinase using the assays described herein. Dosages
20 necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-
25 90% of the time, preferably between 30-90% and most preferably between 50-90%.

In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner
30 of administration and the judgment of the prescribing physician.

d) Packaging

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compound for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Suitable conditions indicated on the label may include treatment of a tumor, inhibition of angiogenesis, treatment of fibrosis, diabetes, and the like.

Additional methods of preparing pharmaceutical formulations of the compounds, methods of determining the amounts of compounds to be administered to a patient, and modes of administering compounds to an organism are disclosed in U.S. Application Serial No. 08/702,232 by Tang, *et al.*, and entitled "Indolinone Combinatorial Libraries and Related Products and Methods for the Treatment of Disease," filed August 23, 1996, and International patent publication number WO 96/22976, by Buzzetti, *et al.*, and entitled "Hydrosoluble 3-Arylidene-2-Oxindole Derivatives as Tyrosine Kinase Inhibitors," published August 1, 1996, both of which are incorporated herein by reference in their entirety, including any drawings. Those skilled in the art will appreciate that such descriptions are applicable to the present invention and can be easily adapted to it.

EXAMPLES

The examples below are non-limiting and are merely representative of various aspects and features of the present invention. The examples describe methods for

synthesizing compounds of the invention and methods for measuring an effect of a compound on the function of protein kinases.

The cells used in the methods are available commercially or from academic labs or were engineered from commercially available cells. The nucleic acid vectors
5 harbored by the cells are also commercially available and the sequences of genes for the various protein kinases are readily accessible in sequence data banks. Thus, a person of ordinary skill in the art can readily recreate the cell lines in a timely manner by combining the commercially available cells, the commercially available nucleic acid vectors, and the protein kinase genes using techniques readily available to persons of
10 ordinary skill in the art.

ASSAY PROCEDURES

The following *in vitro* assays may be used to determine the level of activity and
15 effect of the different compounds of the present invention on one or more of the PKs. Similar assays can be designed along the same lines for any PK using techniques well known in the art.

The cellular/catalytic assays described herein are performed in an ELISA format. The general procedure is as follows: a compound is introduced to cells
20 expressing the test kinase, either naturally or recombinantly, for some period of time after which, if the test kinase is a receptor, a ligand known to activate the receptor is added. The cells are lysed and the lysate is transferred to the wells of an ELISA plate previously coated with a specific antibody recognizing the substrate of the enzymatic phosphorylation reaction. Non-substrate components of the cell lysate are washed away
25 and the amount of phosphorylation on the substrate is detected with an antibody specifically recognizing phosphotyrosine compared with control cells that were not contacted with a test compound. The assay could also be adapted to detection by Western blotting.

The cellular/biologic assays described herein measure the amount of DNA made
30 in response to activation of a test kinase, which is a general measure of a proliferative response. The general procedure for this assay is as follows: a compound is introduced

to cells expressing the test kinase, either naturally or recombinantly, for some period of time after which, if the test kinase is a receptor, a ligand known to activate the receptor is added. After incubation at least overnight, a DNA labeling reagent such as bromodeoxy-uridine (BrdU) or 3H-thymidine is added. The amount of labeled DNA is
5 detected with either an anti-BrdU antibody or by measuring radioactivity and is compared to control cells not contacted with a test compound.

CELLULAR/CATALYTIC ASSAYS

10 Enzyme linked immunosorbent assays (ELISA) may be used to detect and measure the presence of PK activity. The ELISA may be conducted according to known protocols which are described in, for example, Voller, *et al.*, 1980, "Enzyme-Linked Immunosorbent Assay," In: Manual of Clinical Immunology, 2d ed., edited by Rose and Friedman, pp. 359-371 Am. Soc. Of Microbiology, Washington, D.C.

15 The disclosed protocol may be adapted for determining activity with respect to a specific PK, such as *c-kit* kinase. The preferred protocols for conducting the ELISA experiments for the specific PKs, *c-kit* kinase, is provided below. Adaptation of these protocols for determining a compound's activity for other members of the RTK family, as well as for CTKs and STKs, is well within the scope of knowledge of those skilled in
20 the art.

EXAMPLE 1: The Activity of the Compounds of the Invention

The biochemical activity of some of the compounds of the invention were tested
25 using the assays described. The IC₅₀ values were measured for several of the compounds of the invention. The results are shown in Figure 2.

A. MATERIALS AND REAGENTS

- 1) HNTG: 5X stock concentration: 100 mM HEPES pH 7.2, 750 mM NaCl, 50% glycerol, 2.5% Triton X-100.
- 30 2) PBS (Dulbecco's Phosphate-Buffered Saline): Gibco Catalog # 450-1300EB

- 3) 1 X Blocking Buffer: 10 mM TRIS-pH7.5, 1 % BSA, 100 mM NaCl, 0.1% Triton X-100
- 4) 1 X Kinase Buffer: 25 mM HEPES, 100 mM NaCl, 10 mM Mg Cl₂, 6 mM Mn Cl₂.
- 5) PMSF Stock Solution = 100mM (Sigma Catalog # P-7626)
- 6) 10 mM ATP (Bacterial source) Sigma A-7699, 5g.
- 7) UB40 anti-phosphotyrosine mAb.
- 8) HRP conjugated sheep anti-Mouse IgG. (Amersham NA 931)
- 9) ABTS (5Prime-3Prime 7-579844)
- 10) TRIS HCL: Fisher BP 152-5
- 11) NaCl: Fisher S271-10
- 12) Triton X-100: Fisher BP151-100
- 13) Na₃VO₄: Fisher S454-50
- 14) MgCl₂: Fisher M33-500
- 15) MnCl₂: Fisher M87-500
- 16) HEPES: Fisher BP310-500
- 17) Albumin, Bovine (BSA): Sigma A-8551
- 18) TBST Buffer: 50 mM Tris pH 7.2, 150 mM NaCl, 0.1% Triton X-100.
- 19) Goat affinity purified antibody Rabbit IgG (whole molecule): Cappel
- 20) 55641.
- 20) Anti Kit (C-20) rabbit polyclonal IgG antibody: Santa Cruz sc-168
- 21) Kit/CHO cells: CHO cells stably expressing GyrB/Kit, which are grown in standard CHO medium, supplemented with 1mg/ml G418
- 22) Indolinone Compounds: The indolinone compounds were synthesized as set forth in the following application: PCT application number US99/06468, filed March 26, 1999 by Fong, *et al.* and entitled METHODS OF MODULATING TYROSINE PROTEIN KINASE (Lyon & Lyon docket number 231/250 PCT which is hereby incorporated by reference in its entirety including any drawings.

B. PROCEDURE

All of the following steps are conducted at room temperature unless it is specifically indicated. All ELISA plate washing is by rinsing 4x with TBST.

Kit Cell Lysis

5 This procedure is performed 1 hour prior to the start of receptor capture.

1) Wash a >95% confluent 15 cm dish with PBS and aspirate as much as possible.

2) Lyse the cells with 3 ml of 1x HNTG containing 1 mM PMSF/15 cm dish. Scrape the cells from the plate and transfer to a 50 ml centrifuge tube.

10 3) Pool supernatants, and allow to sit, on ice, for one hour with occasional vortexing. Failure to do so will result in an increased background (approximately 3-fold higher).

4) Balance tubes and centrifuge at 10,000 x g for 10 min at 4°C. Remove an aliquot for protein determination

15 5) Perform protein determination as per the SOP for protein determination using the bicinchoninic acid (BCA) method.

ELISA Procedure

1) Coat Corning 96-well ELISA plates with 2 µg per well Goat anti-rabbit antibody in PBS for a total well volume of 100 µl. Store overnight at 4°C.

20 2) Remove unbound Goat anti-rabbit antibody by inverting plate to remove liquid.

3) Add 100 µl of Blocking Buffer to each well. Shake at room temperature for 60 min.

25 4) Wash 4x with TBST. Pat plate on a paper towel to remove excess liquid and bubbles

5) Add 0.2 µg per well of Rabbit anti -Kit antibody diluted in TBST for a total well volume of 100 µl. Shake at room temperature for 60 min.

6) Dilute lysate in HNTG (180 µg lysate/100 µl)

30 7) Add 100 µl of diluted lysate to each well. Shake at room temperature for 60 min.

- 8) Wash 4x with TBST. Pat plate on a paper towel to remove excess liquid and bubbles
 - 9) Dilute compounds/extracts (or as stated otherwise) in 1x kinase buffer, with 5 μ M ATP in a polypropylene 96 well plate
 - 5 10) Transfer 100 μ l of diluted drug to ELISA plate wells. Incubate at room temperature with shaking for 60min.
 - 11) Stop reaction with the addition of 10 μ l of 0.5 M EDTA. Plate is now stable for a reasonable period of time.
 - 12) Wash 4x with TBST. Pat plate on a paper towel to remove excess liquid and bubbles
 - 10 13) Add 100 μ l per well of UB40 (1:2000 dilution in TBST). Incubate 60 min at room temperature, with shaking.
 - 14) Wash 4x with TBST. Pat plate on a paper towel to remove excess liquid and bubbles
 - 15 15) Add 100 μ l per well of sheep anti-mouse IgG - HRP (1:5000 dilution in TBST). Incubate 60 min at room temperature, with shaking.
 - 16) Wash 4x with TBST. Pat plate on a paper towel to remove excess liquid and bubbles
 - 17) Add 100 μ l per well of ABTS. Incubate with shaking for 15-30 min.
 - 20 18) Read assay on Dynatech MR7000 ELISA reader
- Test Filter = 410 nm
- Reference Filter = 630 nm

EXAMPLE 2: The Activity of the Compounds of the Invention

The biochemical activity of two of the compounds of the invention were tested using the assays described below.

Methods:**5 Cell Lines**

MO7E cells, a human myeloid leukemia cell line, were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum and 10 ng/ml each IL-3 and GM-CSF.

Detection of *c-kit* Tyrosine Phosphorylation

10 MO7E cells were serum starved overnight in 0.1% serum. Cells were pre-treated with Compound Eight for 2 hours, or with Compound Six for 22 hours (concurrent with serum starvation), prior to ligand stimulation. Cells were stimulated with 250 ng/ml rh-SCF for 15 minutes. Following stimulation, cells were lysed and immunoprecipitated with an anti-c-kit antibody. Phosphotyrosine and protein levels were determined by
15 western blotting.

MTT Proliferation Assay

MO7E cells were serum starved and pre-treated with compound as described for the phosphorylation experiments. Cells were plated @ 4×10^5 cells/well in a 96 well dish, in 100 μ l RPMI + 10% serum. rh-SCF (100 ng/mL) was added and the plate was
20 incubated for 48 hours. After 48 hours, 10 μ l of 5 mg/ml MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) was added and allowed to incubate for 4 hours. Acid isopropanol (100 μ l of 0.04N HCl in isopropanol) was added and the optical density was measured at a wavelength of 550 nm.

Apoptosis assays

25 MO7E cells were incubated +/- SCF and +/- compound (Compound Six or Compound Eight @ 5 and 25 μ M) in 10% FBS with rh-GM-CSF(10ng/mL) and rh-IL-3 (10ng/mL). Samples were assayed at 24 and 48 hours. To measure activated caspase-3, samples were washed with PBS and permeabilized with ice-cold 70% ethanol. The cells were then stained with PE-conjugated polyclonal rabbit anti-active caspase-3 and
30 analyzed by FACS. To measure cleaved PARP, samples were lysed and analyzed by western blotting with an anti-PARP antibody.

Inhibition of biological functions of c-kit by Compound Eight and Compound Six

Results:

Inhibition of tyrosine phosphorylation of *c-kit*

Compound Eight and Compound Six inhibit tyrosine phosphorylation of *c-kit* in MO7E cells, a human myeloid leukemia cell line, in response to ligand stimulation with stem cell factor (SCF). In Compound Eight treated cells, no inhibition of phosphorylation was observed at 0.01 μM , partial inhibition was observed at 0.1 μM , and complete inhibition was observed at 1 and 10 μM . In Compound Six treated cells, no inhibition of *c-kit* tyrosine phosphorylation was observed at 0.01 μM or 0.1 μM , partial inhibition was observed at 1 μM , and complete inhibition was observed at 10 μM .

Inhibition of *c-kit* mediated proliferation

Compound Eight and Compound Six also inhibit *c-kit* mediated signaling in MO7E cells in an MTT proliferation assay. The IC_{50} value for Compound Eight inhibition of proliferation is approximately 0.5-1.0 μM , and the IC_{50} value for Compound Six is approximately 5-7 μM .

Induction of apoptosis

Compound Eight and Compound Six also induce apoptosis in MO7E cells, in a dose and time dependent fashion. Apoptosis was assessed with two assays: a FACS analysis with an antibody that recognizes activated caspase-3 in cells, which is induced during apoptosis, and a western blotting assay that detects a cleaved fragment of poly (ADP-ribose) polymerase, also induced during apoptosis.

Using the caspase-3 assay, an approximately 50% increase in the number of apoptotic cells was observed at 48 hours, upon SCF stimulation and 25 μM Compound Eight treatment, compared to untreated SCF stimulated cells. A slight effect was observed at 48 hours with 25 μM Compound Eight in the absence of SCF stimulation. Treatment for 24 hours with 25 μM Compound Eight (+/- SCF stimulation), resulted in a measurable but smaller number of apoptotic cells.

Treatment of cells with 5 μM Compound Eight for 24 or 48 hours (+/- SCF stimulation) also resulted in a measurable but smaller number of apoptotic cells.

Similar results were obtained for Compound Six, with the exception of no effect observed with 5 μ M Compound Six at 24 hours, with or without SCF stimulation.

Using the PARP assay, treatment with 25 μ M Compound Eight for 48 hours resulted in the greatest increase in the amount of cleaved PARP. The effect was
5 augmented slightly with SCF stimulation. The 24 hour sample treated with 25 μ M Compound Eight was similar to the 48 hour sample.

Treatment with 5 μ M Compound Eight, at both timepoints, resulted in a very minimal increase in cleaved PARP.

Similar results were obtained for Compound Six.

10

CONCLUSION

One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well
15 as those inherent therein. The molecular complexes and the methods, procedures, treatments, molecules, specific compounds described herein are presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention are defined by the scope of
20 the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

All patents and publications mentioned in the specification are indicative of the
25 levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

The invention illustratively described herein suitably may be practiced in the
30 absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms

“comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group. For example, if X is described as selected from the group consisting of bromine, chlorine, and iodine, claims for X being bromine and claims for X being bromine and chlorine are fully described.

The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.


Other embodiments are within the following claims.

CLAIMS

1. A method for treating or preventing an abnormal condition in an organism, wherein said abnormal condition is associated with an aberration in a signal transduction pathway mediated by a *c-kit* kinase, wherein said method comprises the step of administering to said organism a therapeutically effective amount of an indolinone compound that modulates, *in vitro*, the catalytic activity of *c-kit* kinase.
2. The method of claim 1 wherein said aberration in said signal transduction pathway is mediated by an interaction between said *c-kit* kinase and a natural binding partner, and said indolinone compound modulates, *in vitro*, the interaction between said *c-kit* kinase and said natural binding partner.
3. The method of claim 1 wherein said abnormal condition is a disease related to inappropriate *c-kit* kinase signal transduction.
4. The method of claim 1, wherein said abnormal condition is selected from the group consisting of mastocytosis, the presence of one or more mast cell tumors, asthma, and allergy associated chronic rhinitis.
5. The method of claim 1, wherein said abnormal condition is selected from the group consisting of small cell lung cancer, non-small cell lung cancer, acute myelocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, a colorectal carcinoma, a gastric carcinoma, a gastrointestinal stromal tumor, a testicular cancer, a glioblastoma, and an astrocytoma.
6. The method of claim 1 wherein said organism is a mammal.
7. The method of claim 1 wherein said organism is a human.


8. The method of any one of claims 1, 2 and 3 wherein said indolinone compound is a compound of the structure set forth in Formula I:

(I)




wherein

- (a) Y is selected from the group consisting of oxygen, sulfur and nitrogen substituted with a hydrogen;
- (b) R₁, R₂, R₃, and R₄ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂ NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_n CO₂ R, and CONRR';
- (c) R₅ is selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂ NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_n CO₂ R, CONRR', a six-membered heteroaryl ring system containing 1 or 2 N, O, or S atoms; and a six-membered aryl ring system; and
- (d) R₆, and R₇ are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, aryloxy, alkaryl, alkaryloxy, halogen, trihalomethyl, S(O)R, SO₂ NRR', SO₃R, SR, NO₂, NRR', OH, CN, C(O)R, OC(O)R, NHC(O)R, (CH₂)_n CO₂ R, and CONRR';




and



9. The method of any one of claims 1, 2 and 3 wherein said indolinone compound is a compound of the structure set forth in Formula II:

(II)



5

wherein

(a) Y is selected from the group consisting of sulfur and nitrogen substituted with a hydrogen;

(b) R₁ is independently selected from the group consisting of hydrogen and methyl;


(c) R₂ is independently selected from the group consisting of hydrogen, chlorine, bromine, -C(O)CH₃, -SO₂NH₂, and SO₂N(CH₃)₂;

(d) R₃ is independently selected from the group consisting of hydrogen, methyl, and -CH₂CH₂COOH; and


(e) R₄ and R₅ are independently selected from the group consisting of hydrogen, methyl, -CH₂CH₂COOH, and substituents that when taken together form a six-membered aliphatic or aromatic ring.

10. The method of any one of claims 1, 2 and 3 wherein said indolinone compound is selected from the group consisting of compounds


(IV)




(V)



5 (VI)




(VII)




10

(VIII)




(IX)


15



(X)




(XI)




5

(XII)




10


(XIII)



(XIV)




(XV)




5

(XVI)




10

(XVII)




15

(XVIII)




5

and XLIX



10

Figure 1



CSF-1r/ *c-fms*
 SCFr/ *c-kit*
flt-3/flk-2

Figure 2

Compound No.	<i>c-kit</i> Kinase IC ₅₀ (nM)
Compound Thirteen	240
Compound One	4.3
Compound Nine	540
Compound Eleven	770
Compound Two	88
Compound Ten	0.14
Compound Seven	0.00042
Compound Five	45
Compound Three	160
Compound Four	37
Compound Twelve	15
Compound Six	2.5
Compound Eight	52

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number
WO 01/45689 A3

(51) International Patent Classification⁷: **A61K 31/40**,
A61P 35/00, 37/08, 11/06

(21) International Application Number: PCT/US00/35009

(22) International Filing Date:
22 December 2000 (22.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/171,693 22 December 1999 (22.12.1999) US

(71) Applicant (for all designated States except US): **SUGEN, INC.** [US/US]; 230 East Grand Avenue, South San Francisco, CA 94080-4811 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIPSON, Ken** [US/US]; 733 Costa Rica Avenue, San Mateo, CA 64402 (US). **MCMAHON, Gerald** [US/US]; P.O. Box 807, Kenwood, CA 94542 (US).

(74) Agent: **ISACSON, John, P.**; Foley and Lardner, 3000 K Street N.W., Suite 500, Washington, DC 20007-5109 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
3 January 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INDOLINONE DERIVATIVES FOR MODULATION OF C-KIT TYROSINE PROTEIN KINASE

(57) Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity *c-kit* kinase.

WO 01/45689 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/35009

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/40 A61P35/00 A61P37/08 A61P11/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 880 141 A (TANG PENG CHO ET AL) 9 March 1999 (1999-03-09) column 3, line 35 -column 4, line 24 column 4, line 35 column 6, line 29 - line 44 column 6, line 45 -column 7, line 26 claims 1-7	8-10
X	WO 99 61422 A (SUGEN INC) 2 December 1999 (1999-12-02) page 1, line 13 - line 19 page 10, line 11 -page 11, line 26 page 31, line 12 - line 17 tables 1,2 page 45, line 22 - line 30 page 216, line 5 -page 218, line 19 claims 1-24	8-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

30 May 2001

Date of mailing of the international search report

15.06.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Taylor, G.M.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/35009

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 792 783 A (TANG PENG CHO ET AL) 11 August 1998 (1998-08-11) abstract column 4, line 66 -column 5, line 38 column 13, line 13 -column 15, line 11 claims 1-28	8-10
P,X	WO 00 56709 A (MILLER TODD ANTHONY ;LIANG CONGXIN (US); SUGEN INC (US); TANG PENG) 28 September 2000 (2000-09-28) cited in the application abstract page 24, line 19 -page 35, line 1 table 3 page 114ff, compounds IN-008, -009, -023, -024 claims 18-39	8-10

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/35009

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-7
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-7

Present claims 1-7 relate to the treatment of diseases characterised by reference to a mechanism of action, namely the modulation of the catalytic activity of c-kit kinase and diseases mediated by this kinase.

The claims cover all diseases involving c-kit kinase, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of diseases involving this kinase and/or methods for identifying diseases falling within this definition.

Furthermore, the application lacks sufficient support (Art. 6 PCT) for the use of any indolinone compound (claim 1).

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the medical method by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products as defined in claims 8-10 for the treatment of those diseases listed in claims 4 and 5.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

Inter. Appl. No.

PCT/US 00/35009

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5880141	A	09-03-1999	AT 200863 T	15-05-2001
			AU 706597 B	17-06-1999
			AU 6044196 A	30-12-1996
			BR 9606410 A	30-12-1997
			CA 2192797 A	19-12-1996
			DE 29623744 U	30-09-1999
			EP 0769947 A	02-05-1997
			EP 0934931 A	11-08-1999
			HU 9701694 A	28-06-1999
			JP 2000026412 A	25-01-2000
			JP 10504323 T	28-04-1998
			NO 965377 A	12-02-1997
			NZ 310109 A	28-01-1999
			WO 9640116 A	19-12-1996
			US 6225335 B	01-05-2001
			US 5792783 A	11-08-1998
			US 5883116 A	16-03-1999
			US 5834504 A	10-11-1998
			US 5886020 A	23-03-1999
			US 5883113 A	16-03-1999
WO 9961422	A	02-12-1999	AU 4410299 A	13-12-1999
			EP 1082305 A	14-03-2001
			NO 20005916 A	29-01-2001
US 5792783	A	11-08-1998	US 5880141 A	09-03-1999
			AT 200863 T	15-05-2001
			AU 706597 B	17-06-1999
			AU 6044196 A	30-12-1996
			BR 9606410 A	30-12-1997
			CA 2192797 A	19-12-1996
			DE 29623744 U	30-09-1999
			EP 0769947 A	02-05-1997
			EP 0934931 A	11-08-1999
			HU 9701694 A	28-06-1999
			JP 2000026412 A	25-01-2000
			JP 10504323 T	28-04-1998
			NO 965377 A	12-02-1997
			NZ 310109 A	28-01-1999
			WO 9640116 A	19-12-1996
			US 6225335 B	01-05-2001
			US 5883116 A	16-03-1999
			US 5834504 A	10-11-1998
			US 5886020 A	23-03-1999
			US 5883113 A	16-03-1999
WO 0056709	A	28-09-2000	AU 3770000 A	09-10-2000